A clinician describes using 9LA as a trial for patients with many asymptomatic brain metastases, checking intracranial response at one-month intervals and avoiding whole-brain radiation when possible. Carbone agrees 9LA patients with or without brain metastases did just as well, and one speaker reports sustained responses over a year.
Carbone says trial patients are fit, but real-world frailty or renal problems may favor less chemotherapy. He does not use age alone to withhold dual immunotherapy from patients over 80 with good performance and organ function, though interstitial lung disease or aggressive autoimmune disease may make dual immunotherapy a poor fit.
Carbone says STK11 and KEAP1 mutations often mark immune-cold, PD-L1-negative tumors where dual immunotherapy may have extra activity. But he warns mutation testing is imperfect: many mutated STK11 tumors retain function, so high PD-L1 plus STK11 alone still pushes him toward single immunotherapy for first-line treatment.
Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.
Carbone points to Keynote 407 five-year data where PD-L1-negative squamous tumors did so poorly that more control-arm patients were alive than treated patients. In his practice, he uses the 9LA dual immunotherapy regimen in that setting for those patients because long-term survival with chemoimmunotherapy is unimpressive.
Carbone says choosing between dervatremi and ipinevo is barely a choice because the dervatremi data are weaker, especially in squamous disease where the same signal is absent. Based on current evidence, he personally uses the ipinevo combination rather than dervatremi in his clinic for first-line NSCLC.
